Takeaways: The Canadian approval expands Epkinly into a second major lymphoma indication (after DLBCL), giving AbbVie a bispecific‑based triplet option in relapsed/refractory follicular ly...
Takeaways: The C-POST data – 68% reduction in recurrence or death versus placebo – gives Regeneron a strong clinical story to push Libtayo earlier in the treatment pathway,...
